Wang Bond: There is uncertainty in the progress and results of innovative drug clinical trials, as well as in the future market competition situation of the products.

Sina Finance reported on March 31 that Wanbangde announced that the company's stock has had a deviation in the closing price for three consecutive trading days, with a cumulative increase of more than 20%, which is considered abnormal stock market volatility. After verification, the company's previously disclosed information does not require correction, and its operations are normal. The controlling shareholder and actual controller are currently planning an agreement transfer related to the company's shares, which will not result in a change in the company's control. As of the date of this announcement, the related matters are still in the planning stage, the formal agreement has not been signed, and there is uncertainty. The company's pharmaceutical manufacturing business and medical device business are operating normally. Research and development of innovative drugs involve high investment, high risk, and long cycles. The progress and results of clinical trials, as well as the future market competition for products, are uncertain and can be influenced by unpredictable factors.